Results 91 to 100 of about 23,301 (197)

Population Pharmacokinetics of Rituximab in Treatment‐Naïve Chinese Patients With Diffuse Large B‐cell Lymphoma During Induction Therapy: Clinical Implications

Clinical and Translational Science, Volume 19, Issue 8, August 2026.
A schematic summary of the population pharmacokinetic model of rituximab in treatment‐naïve Chinese DLBCL patients during induction therapy, along with key clinical implications. ABSTRACT This study aimed to establish and validate a population pharmacokinetic model for rituximab during induction therapy in treatment‐naive patients with diffuse large B ...
Wan‐Yi Zhou, Jing Ling, Meng‐Meng Guan, Ying Qu, Ying‐Hui Dan, Rong Chen   +5 more
wiley   +1 more source

Pretreatment With BTK Inhibitors Improved the Sensitivity of DLBCL Cells to CAR‐T Cells in a Coculture System by Downregulating the Polarisation of M2 Macrophages

Journal of Cellular and Molecular Medicine, Volume 30, Issue 15, August 2026.
ABSTRACT The tumour microenvironment (TME) of relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) patients is associated with resistance of DLBCL cells to CD19 CAR‐T cells. How to improve TME in DLBCL and improve the efficacy of CAR‐T cell therapy remains to be further explored.
Yao Qi, Xuemei Fan, Jia Wang, Xin Li, Juan Mu, Rui Cui, Qi Deng   +6 more
wiley   +1 more source

ANCA positive pauci-immune glomerulonephritis as presenting feature of mantle cell lymphoma: A case report and review of literature

Nefrología
Kidney involvement in mantle cell lymphoma is rare. We report a case of mantle cell lymphoma diagnosed after rapidly progressive glomerulonephritis with biopsy-proven paraneoplastic anti-neutrophil cytoplasmic antibody positive pauci-immune cresentic ...
Gizem Kumru, Merve Yüksel, Yasemin Geriş, Emine Selin Yıldırım, Saba Kiremitci, Işınsu Kuzu, Önder Arslan   +6 more
doaj   +1 more source

Chimeric antigen receptor T-cell therapy for aggressive B-cell lymphomas

Frontiers in Oncology
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-cell ...
Bei Hu, Victoria Korsos, M. Lia Palomba, M. Lia Palomba   +3 more
doaj   +1 more source

Mantle cell leukemia as a cause of leukostasis

Blood and Lymphatic Cancer: Targets and Therapy, 2011
Daniel Smith1, Christian Cable2, Cary Chisholm1, Walter Linz1, William Koss1, Sheila Dobin1, Edward Rappaport11Department of Pathology, 2Internal Medicine, Scott and White Healthcare/Texas A & M Health Science Center College of Medicine, Temple ...
Rappaport E, Dobin S, Koss W, Linz W, Chisholm C, Cable C, Smith D   +6 more
doaj  

Leukemic Non-Nodal Mantle Cell Lymphoma Presenting with Traumatic Splenic Rupture. [PDF]

Hematol Rep
Haque M, Amraei R, Rozenova KA.
europepmc   +1 more source

Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (HMGCR) Immune-Mediated Necrotizing Myopathy With Subsequent Diagnosis of Mantle Cell Lymphoma. [PDF]

Cureus
Zhao C, Duffield A, Toz B.
europepmc   +1 more source

Extracorporeal Cytokine Hemadsorption for the Treatment of Severe Steroid Refractory Cytokine Release Syndrome Secondary to T-Cell Immunotherapy for B-Cell Malignancies: A Case Series. [PDF]

Hematol Oncol
Cavallaro G, Ferrari S, Pollastri A, Di Credico E, Meli C, Rondi M, Putelli A, Lussana F, Grassi A, Rambaldi A, Valetti TM, Riva I, Gritti G.   +12 more
europepmc   +1 more source

Correction: A novel immune model predicts the prognosis of mantle cell lymphoma. [PDF]

Front Med (Lausanne)
Hao X, Zhang Y, Qi W, Zhu M, Wang J, Yang P, Zhang W, Jing H.   +7 more
europepmc   +1 more source

Beyond the Nodes: Atypical Presentations of Non-Hodgkin's Lymphoma Across Organs. [PDF]

Cureus
A S, D'Cruze L, Archana B, Sundaram S, Priyathersini N.   +4 more
europepmc   +1 more source